---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-011768"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T04:54:05.850841+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics Q2 cash $60.2M; FDA clears GMI-1687 IND; uproleselan Phase 3 data expected mid-2023

## Summary
- Cash and cash equivalents $60.2M as of June 30, 2022, down from $90.3M at Dec 31, 2021.
- R&D expenses $8.0M (down from $10.2M YoY) due to lower uproleselan trial costs after enrollment ended.
- G&A expenses $5.5M (up from $4.2M) for commercial start-up costs for uproleselan.
- FDA cleared IND for GMI-1687 in sickle cell disease; company seeks licensing partner.
- Phase 3 uproleselan trial (n=388) on track; survival events trigger expected mid-2023 with top-line data soon after.

## SEC filing metadata
- accession: 0001558370-22-011768
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837022011768/0001558370-22-011768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837022011768/glyc-20220803x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-011768
- JSON: https://secwatch.observer/filing/0001558370-22-011768.json
- Plain text: https://secwatch.observer/filing/0001558370-22-011768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.